Genetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review

References

• Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S55–S60. doi:10.1097/IGC.0000000000000228
   PubMed Web of Science ®Google Scholar
• Boussios S, Attygalle A, Hazell S, et al. Malignant ovarian germ cell tumors in postmenopausal patients: the royal Marsden experience and literature review. Anticancer Res. 2015;35(12):6713–6722.
   PubMed Web of Science ®Google Scholar
• Boussios S, Zarkavelis G, Seraj E, Zerdes I, Tatsi K, Pentheroudakis G. Non-epithelial ovarian cancer: elucidating uncommon gynaecological malignancies. Anticancer Res. 2016;36(10):5031–5042. doi:10.21873/anticanres.11072
   PubMed Web of Science ®Google Scholar
• Zhao S, Bellone S, Lopez S, et al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016;113(43):12238–12243. doi:10.1073/pnas.1614120113
   PubMed Web of Science ®Google Scholar
• Popic V, Salari R, Hajirasouliha I, Kashef-Haghighi D, West RB, Batzoglou S. Fast and scalable inference of multi-sample cancer lineages. Genome Biol. 2015;16(1):91. doi:10.1186/s13059-015-0647-8
   PubMed Web of Science ®Google Scholar
• Miura S, Vu T, Deng J, et al. Power and pitfalls of computational methods for inferring clone phylogenies and mutation orders from bulk sequencing data. Sci Rep. 2020;10(1):3498. doi:10.1038/s41598-020-59006-2
   PubMed Web of Science ®Google Scholar
• Carnevali IW, Cimetti L, Sahnane N, et al. Two cases of carcinosarcomas of the ovary involved in hereditary cancer syndromes. Int J Gynecol Pathol. 2017;36(1):64–70. doi:10.1097/PGP.0000000000000290
   PubMed Web of Science ®Google Scholar
• Montalvo-Esquivel G, Chanona-Vilchis JG, Herrera-Gómez A, Meneses-García AA, Isla-Ortiz D. Primary ovarian carcinosarcoma. Report of eight cases. Ginecol Obstet Mex. 2014;82(7):483–489.
   PubMedGoogle Scholar
• Gotoh O, Sugiyama Y, Takazawa Y, et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun. 2019;10(1):4965. doi:10.1038/s41467-019-12985-x
   PubMed Web of Science ®Google Scholar
• Mikami Y. Paradigm shift in ovarian tumor pathology from the view of genomic abnormalities. Gan To Kagaku Ryoho. 2016;43(3):286–289.
   PubMedGoogle Scholar
• Terada KY, Ahn HJ, Kessel B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol. 2016;27(3):e25. doi:10.3802/jgo.2016.27.e25
   PubMed Web of Science ®Google Scholar
• Weinberger V, Bednarikova M, Cibula D, Zikan M. Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. Expert Rev Anticancer Ther. 2016;16(12):1311–1321. doi:10.1080/14737140.2016.1247699
   PubMed Web of Science ®Google Scholar
• Seidman JD. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer). Int J Gynecol Pathol. 2015;34(2):112–120. doi:10.1097/PGP.0000000000000123
   PubMed Web of Science ®Google Scholar
• Rewsuwan S, Satabongkoch N, Suprasert P, Khunamornpong S. Ovarian carcinosarcoma and its association with mature cystic teratoma and primary tubal carcinoma. Case Rep Pathol. 2016;2016:2605045. doi:10.1155/2016/2605045
   PubMedGoogle Scholar
• See SHC, Behdad A, Maniar KP, Blanco LZ. Ovarian carcinosarcoma and concurrent serous tubal intraepithelial carcinoma with next-generation sequencing suggesting an origin from the fallopian tube. Int J Surg Pathol. 2019;27(5):574–579. doi:10.1177/1066896919838347
   PubMed Web of Science ®Google Scholar
• Moss EL, Evans T, Pearmain P, et al. Should all cases of high-grade serous ovarian, tubal, and primary peritoneal carcinomas be reclassified as tubo-ovarian serous carcinoma? Int J Gynecol Cancer. 2015;25(7):1201–1207. doi:10.1097/IGC.0000000000000477
   PubMed Web of Science ®Google Scholar
• Ardighieri L, Mori L, Conzadori S, et al. Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. Virchows Arch. 2016;469(1):61–69. doi:10.1007/s00428-016-1933-x
   PubMed Web of Science ®Google Scholar
• Wang WP, Li N, Zhang YY, et al. Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma. Cancer Manag Res. 2018;10:1959–1968. doi:10.2147/CMAR.S166524
   PubMed Web of Science ®Google Scholar
• Cicin I, Ozatli T, Turkmen E, et al. Predictive and prognostic factors in ovarian and uterine carcinosarcomas. Balkan Med J. 2016;33(5):517–524. doi:10.5152/balkanmedj.2016.151268
   PubMed Web of Science ®Google Scholar
• Chung YS, Park SY, Lee JY, et al. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). BMC Cancer. 2019;19(1):341. doi:10.1186/s12885-019-5514-7
   PubMed Web of Science ®Google Scholar
• Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004;100(10):2148–2153. doi:10.1002/cncr.20256
   PubMed Web of Science ®Google Scholar
• Kanis MJ, Kolev V, Getrajdman J, Zakashansky K, Cohen C, Rahaman J. Carcinosarcoma of the ovary: a single institution experience and review of the literature. Eur J Gynaecol Oncol. 2016;37(1):75–79.
   PubMed Web of Science ®Google Scholar
• Yalcin I, Meydanli MM, Turan AT, et al. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment. Int J Clin Oncol. 2018;23(2):329–337. doi:10.1007/s10147-017-1215-x
   PubMed Web of Science ®Google Scholar
• Heinzelmann-Schwarz V, Kind AB, Vetter M, et al. Should MMMT still be treated with adjuvant taxane-based combination chemotherapy? J Cancer Res Clin Oncol. 2020;146(3):695–704. doi:10.1007/s00432-019-03091-y
   PubMed Web of Science ®Google Scholar
• Boussios S, Karathanasi A, Zakynthinakis-Kyriakou N, et al. Ovarian carcinosarcoma: current developments and future perspectives. Crit Rev Oncol Hematol. 2019;134:46–55. doi:10.1016/j.critrevonc.2018.12.006
   PubMed Web of Science ®Google Scholar
• Brackmann M, Stasenko M, Uppal S, Erba J, Reynolds RK, McLean K. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. BMC Cancer. 2018;18(1):172. doi:10.1186/s12885-018-4082-6
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;93(2):336–339. doi:10.1016/j.ygyno.2004.01.007
   PubMed Web of Science ®Google Scholar
• Glaser G, Weroha SJ, Becker MA, et al. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. PLoS One. 2015;10(5):e0126867. doi:10.1371/journal.pone.0126867
   PubMed Web of Science ®Google Scholar